Lentigen and Expression Therapeutics will develop two types of treatments for hemophilia: a novel chimeric factor VIII protein for direct injection and a cell therapy that may permanently correct the disorder.
Trent Spencer, president of Expression Therapeutics, said: “The platform technology developed by Expression Therapeutics will be used to advance the treatment of hemophilia A.
“By combining our high expression Factor VIII technology with Lentigen’s protein expression and gene transfer capabilities, we are confident Lentigen is the ideal partner to help bring this technology to the clinic and marketplace.”